Global Transplant Diagnostics Market to rise at a 6.5% CAGR from 2024 to 2034, reaching a Value of US$ 8.5 Billion

Rising demand for non-invasive transplant diagnostics spurs innovation. AI, biomarkers, and big data drive precision, meeting global needs and patient-centric care. By technology, the molecular assay technologies segment accounted for the largest share of the transplant diagnostics market during the forecast period

NEWARK, Del, Feb. 05, 2024 (GLOBE NEWSWIRE) — The global transplant diagnostics market is anticipated to reach a valuation of US$ 4.5 billion in 2024, driven by regulatory initiatives for standardization and control in transplant diagnostics. The trend is expected to create new opportunities for the market, leading to a projected CAGR of 6.5% between 2024 and 2034, and reaching a total valuation of approximately US$ 8.5 billion by 2034.

The increasing focus on non-invasive diagnostics provides fertile ground for transplant diagnostics to flourish. Development of non-invasive or minimally invasive diagnostic techniques for transplant monitoring is a growing trend. Blood based biomarker assays and imaging technologies that reduce the need for invasive procedures are gaining attention.

Request a Sample of this Report Now:

The persistent shortage of organs available for transplantation globally highlights the need for efficient and accurate transplant diagnostics. Addressing this shortage may drive further innovation in diagnostics technologies to maximize the utilization of available organs. The increasing awareness and acceptance of cell-based therapies, such as stem cell transplantation, create new opportunities for transplant diagnostics. The therapies often require advanced compatibility testing and monitoring.

The integration of artificial intelligence and machine learning in transplant diagnostics holds the potential to enhance data analysis, improve prediction models, and contribute to more precise and personalized diagnostics. The growing recognition of the importance of pre transplant testing in assessing potential risks and improving patient outcomes has driven an increase in demand for diagnostic solutions before transplantation procedures.

Cross border organ transplants have become more prevalent, leading to an increased need for standardized and efficient transplant diagnostics. The trend emphasizes the importance of compatibility testing in diverse patient populations. Ongoing research in biomarker discovery for transplant diagnostics aims to identify reliable indicators of organ rejection or complications. The discovery of new biomarkers can significantly improve the accuracy and early detection of potential issues post-transplant.

The integration of big data analytics in transplant diagnostics allows for the analysis of large datasets to identify patterns, predict outcomes, and optimize transplant strategies. Big data can enhance decision making and personalized treatment plans. There is a growing emphasis on patient centric approaches in transplant care, with a focus on involving patients in decision making and treatment planning. The trend may lead to the development of user friendly diagnostics and remote monitoring tools for patients.

Key Takeaways from the Transplant Diagnostics Market Study

  • The global transplant diagnostics market was valued at US$ 4.2 billion in 2023.
  • From 2019 to 2023, the market demand expanded at a CAGR of 8.1%.
  • The market in South Korea is expected to expand at a CAGR of 8.0% through 2034.
  • By product and service, the instruments segment to account for a CAGR of 6.3% through 2034.
  • By screening type, pre-transplant diagnostics to be prominent, expanding at a CAGR of 6.1% until 2034.
  • Transplant diagnostics scope in the United States is significant, expected to rise at a 6.8% CAGR through 2034

“Advances in organ preservation technologies, such as ex vivo perfusion systems, provide traction to the transplant diagnostics market. Improved preservation methods can extend the viability of organs and provide more time for comprehensive diagnostic assessments,” remarks Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Click Here to Request Methodology!

Recent Development from the Transplant Diagnostics Market:

  • In 2022, Biocartis and Ophiomics forged a collaboration aimed at advancing the commercialization of HepatoPredict. The prognostic gene expression signature test is designed to discern patients who will experience benefits from liver transplantation.

Top 11 Key Companies Profiled in the Transplant Diagnostics Market:        

  1. Becton Dickinson and Company
  2. Bio-Rad Laboratories Inc.
  3. Illumina Inc.
  4. Immucor Transplant Diagnostics Inc.
  5. Thermo Fisher Scientific Inc.
  6. CareDx
  7. Affymetrix Inc.
  8. Linkage Biosciences
  9. Abbott Laboratories Inc.
  10. BioMérieux S.A.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global transplant diagnostics market, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.

To understand opportunities in the transplant diagnostics market, the market is segmented on the basis of product and service (instruments, reagents and consumables), screening type (pre transplant, post-transplant), and organ type (kidney, liver, heart, lung, pancreas), across seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, and Middle East & Africa (MEA)).

Buy a Complete Research Report

Segmentation Analysis of the Transplant Diagnostics Market

By Product and Service:

  • Instruments
  • Reagents and Consumables

By Screening Type:

  • Pre Transplant
  • Post-Transplant

By Organ Type:

  • Kidney
  • Liver
  • Heart
  • Lung
  • Pancreas

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East and Africa

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with the objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the market lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.


Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Have a Look at the Related Report from the Transplant Diagnostics Market:

  • Tissue Diagnostics Market was valued at US$ 32.0 Billion in 2021 and is set to expand at a healthy CAGR of 12.8% during 2022-2032, with a market valuation of US$ 120.2 Billion by 2032.
  • Transplant Monitoring Kits Market is estimated to secure a valuation of US$ 5.2 Billion in 2023 and is estimated to rise to US$ 8.2 billion by 2033. The market is anticipated at a CAGR of 4.6% during the forecast period. 
  • Poultry Diagnostics Market demand is subjected to record a CAGR of 10.5%. The market revenue is likely to be valued at US$ 590 million in 2023 and exhibit a revenue growth of US$ 1.6 billion by 2033.
  • Chlamydia Diagnostics Market garnered a market value of US$ 1.17 Billion in 2022 and is expected to accumulate a market value of US$ 3.69 Billion by registering a CAGR of 11% in the forecast period 2023 to 2033.
  • Cancer Diagnostics Market is projected to expand and gain a global market valuation of US$ 55.71 billion. Considering this increasing growth and demand in the global market, the market is expected to reach US$ 126 billion by 2033.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani 

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
LinkedInTwitterBlogs | YouTube

Primary Logo

Originally published at